Ronnie Tung-Ping Poon1, Tom Tan-To Cheung1, Philip Chong-Hei Kwok2, Ann-Shing Lee3, Tat-Wing Li4, Kwok-Loon Loke5, Stephen Lam Chan6, Moon-Tong Cheung7, Tak-Wing Lai8, Chin-Cheung Cheung9, Foon-Yiu Cheung10, Ching-Kong Loo11, Yiu-Kuen But12, Shing-Jih Hsu12, Simon Chun-Ho Yu13, Thomas Yau12. 1. Department of Surgery, The University of Hong Kong, Queen Mary Hospital, Hong Kong, SAR (China). 2. Department of Radiology and Imaging, Queen Elizabeth Hospital, Hong Kong, SAR (China). 3. Department of Clinical Oncology, Tuen Mun Hospital, Hong Kong, SAR (China). 4. Department of Medicine, Pamela Youde Nethersole Eastern Hospital, Hong Kong, SAR (China). 5. Department of Radiology and Organ Imaging, United Christian Hospital, Hong Kong, SAR (China). 6. Department of Clinical Oncology, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, SAR (China). 7. Department of Surgery, Queen Elizabeth Hospital, Hong Kong, SAR (China). 8. Department of Surgery, Princess Margaret Hospital, Hong Kong, SAR (China). 9. Department of Surgery, Tuen Mun Hospital, Hong Kong, SAR (China). 10. Department of Clinical Oncology, Pamela Youde Nethersole Eastern Hospital, Hong Kong, SAR (China). 11. Department of Medicine and Geriatrics, Kwong Wah Hospital, Hong Kong, SAR (China). 12. Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, SAR (China). 13. Department of Imaging and Interventional Radiology, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, SAR (China).
Abstract
BACKGROUND: Hepatocellular carcinoma (HCC) is particularly prevalent in Hong Kong because of the high prevalence of chronic hepatitis B (CHB) infection; HCC is the fourth commonest cancer in men and the seventh commonest in women, and it is the third leading cause of cancer death in Hong Kong. The full spectrum of treatment modalities for HCC is available locally; however, there is currently no local consensus document detailing how these modalities should be used. SUMMARY: In a series of meetings held between May and October 2013, a multidisciplinary group of Hong Kong clinicians - liver surgeons, medical oncologists, clinical oncologists, hepatologists, and interventional radiologists - convened to formulate local recommendations on HCC management. These recommendations consolidate the most current evidence pertaining to HCC treatment modalities, together with the latest thinking of practicing clinicians engaged in HCC management, and give detailed guidance on how to deploy these modalities effectively for patients in various disease stages. KEY MESSAGES: Distinct from other regional guidelines, these recommendations provide guidance on the use of antiviral therapy to reduce the incidence of HCC in CHB patients with cirrhosis and to reduce recurrence of CHB-related HCC.
BACKGROUND:Hepatocellular carcinoma (HCC) is particularly prevalent in Hong Kong because of the high prevalence of chronic hepatitis B (CHB) infection; HCC is the fourth commonest cancer in men and the seventh commonest in women, and it is the third leading cause of cancer death in Hong Kong. The full spectrum of treatment modalities for HCC is available locally; however, there is currently no local consensus document detailing how these modalities should be used. SUMMARY: In a series of meetings held between May and October 2013, a multidisciplinary group of Hong Kong clinicians - liver surgeons, medical oncologists, clinical oncologists, hepatologists, and interventional radiologists - convened to formulate local recommendations on HCC management. These recommendations consolidate the most current evidence pertaining to HCC treatment modalities, together with the latest thinking of practicing clinicians engaged in HCC management, and give detailed guidance on how to deploy these modalities effectively for patients in various disease stages. KEY MESSAGES: Distinct from other regional guidelines, these recommendations provide guidance on the use of antiviral therapy to reduce the incidence of HCC in CHB patients with cirrhosis and to reduce recurrence of CHB-related HCC.
Entities:
Keywords:
Consensus; Hepatocellular carcinoma; Hong Kong
Authors: Bruno Sangro; Livio Carpanese; Roberto Cianni; Rita Golfieri; Daniele Gasparini; Samer Ezziddin; Philipp M Paprottka; Francesco Fiore; Mark Van Buskirk; Jose Ignacio Bilbao; Giuseppe Maria Ettorre; Rita Salvatori; Emanuela Giampalma; Onelio Geatti; Kai Wilhelm; Ralf Thorsten Hoffmann; Francesco Izzo; Mercedes Iñarrairaegui; Carlo Ludovico Maini; Carlo Urigo; Alberta Cappelli; Alessandro Vit; Hojjat Ahmadzadehfar; Tobias Franz Jakobs; Secondo Lastoria Journal: Hepatology Date: 2011-06-30 Impact factor: 17.425
Authors: T Peter Kingham; Ami M Karkar; Michael I D'Angelica; Peter J Allen; Ronald P Dematteo; George I Getrajdman; Constantinos T Sofocleous; Stephen B Solomon; William R Jarnagin; Yuman Fong Journal: J Am Coll Surg Date: 2012-06-16 Impact factor: 6.113
Authors: Ghassan K Abou-Alfa; Philip Johnson; Jennifer J Knox; Marinela Capanu; Irina Davidenko; Juan Lacava; Thomas Leung; Bolorsukh Gansukh; Leonard B Saltz Journal: JAMA Date: 2010-11-17 Impact factor: 56.272
Authors: R Lencioni; M Kudo; S-L Ye; J-P Bronowicki; X-P Chen; L Dagher; J Furuse; J F Geschwind; L Ladrón de Guevara; L L de Guevara; C Papandreou; A J Sanyal; T Takayama; S K Yoon; K Nakajima; F Cihon; S Heldner; J A Marrero Journal: Int J Clin Pract Date: 2012-07 Impact factor: 2.503
Authors: John P Duffy; Andrew Vardanian; Elizabeth Benjamin; Melissa Watson; Douglas G Farmer; Rafik M Ghobrial; Gerald Lipshutz; Hasan Yersiz; David S K Lu; Charles Lassman; Myron J Tong; Jonathan R Hiatt; Ronald W Busuttil Journal: Ann Surg Date: 2007-09 Impact factor: 12.969
Authors: Laura M Kulik; Brian I Carr; Mary F Mulcahy; Robert J Lewandowski; Bassel Atassi; Robert K Ryu; Kent T Sato; Al Benson; Albert A Nemcek; Vanessa L Gates; Michael Abecassis; Reed A Omary; Riad Salem Journal: Hepatology Date: 2008-01 Impact factor: 17.425
Authors: Tan To Cheung; Ferdinand S K Chu; Caroline R Jenkins; Dickson S F Tsang; Kenneth S H Chok; Albert C Y Chan; Thomas C C Yau; See Ching Chan; Ronnie T P Poon; Chung Mau Lo; Sheung Tat Fan Journal: World J Surg Date: 2012-10 Impact factor: 3.352
Authors: A Bauschke; A Altendorf-Hofmann; M Freesmeyer; T Winkens; C Malessa; J-H Schierz; U Teichgraeber; U Settmacher Journal: Chirurg Date: 2016-11 Impact factor: 0.955
Authors: Pierce K H Chow; Su Pin Choo; David C E Ng; Richard H G Lo; Michael L C Wang; Han Chong Toh; David W M Tai; Brian K P Goh; Jen San Wong; Kiang Hiong Tay; Anthony S W Goh; Sean X Yan; Kelvin S H Loke; Sue Ping Thang; Apoorva Gogna; Chow Wei Too; Farah Gillian Irani; Sum Leong; Kiat Hon Lim; Choon Hua Thng Journal: Liver Cancer Date: 2016-03-17 Impact factor: 11.740
Authors: Tom Tan-To Cheung; Philip Chong-Hei Kwok; Stephen Chan; Chin-Cheung Cheung; Ann-Shing Lee; Victor Lee; Hoi-Ching Cheng; Nam-Hung Chia; Charing C N Chong; Tak-Wing Lai; Ada L Y Law; Mai-Yee Luk; Chi Chung Tong; Thomas C C Yau Journal: Liver Cancer Date: 2018-01-25 Impact factor: 11.740